Principal components analysis on genes related to inflammasome complex and microglial activation in the hypothalamus of obese mice treated with semaglutide (GLP-1 analog).
在接受semaglutide(GLP-1 類似物)治療的肥胖小鼠下丘腦中,與炎症小體複合體和小膠質細胞活化相關基因的主成分分析。
Brain Res 2024-09-07
Absorption, Distribution, Metabolism, and Excretion of Tirzepatide in Humans, Rats, and Monkeys.
Tirzepatide 在人類、老鼠和猴子中的吸收、分佈、代謝和排泄。
Eur J Pharm Sci 2024-09-07
GLP-1 receptor agonists may enhance the effects of desmopressin in individuals with AVP deficiency: a case series and proposed mechanism.
GLP-1 受體激動劑可能增強缺乏抗利尿激素 (AVP) 個體中 desmopressin 的效果:案例系列及提出的機制。
Pituitary 2024-09-06
Update on eating disorders and disordered eating behaviors in metabolic bariatric surgery patients.
代謝性減重手術患者的飲食失調及異常飲食行為最新進展。
Curr Opin Psychiatry 2024-09-06
Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.
評估使用固定比例的 insulin degludec 和 liraglutide 進行代謝介入的 2 型糖尿病緩解情況:一項隨機對照試驗。
Diabetes Obes Metab 2024-09-06
Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial.
beinaglutide 注射劑的藥物動力學及安全性特徵,針對超重/肥胖成人:來自 I 期臨床試驗的結果。
Front Pharmacol 2024-09-06
Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.
使用 Glucagon-Like Peptide-1 受體激動劑的患者在選擇性食道胃十二指腸鏡檢查後吸入性肺炎的風險。
Cureus 2024-09-06
The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Adolescents Without Diabetes Mellitus: A Systematic Review and Meta-Analysis.
GLP-1 受體激動劑在無糖尿病的超重/肥胖青少年中的抗肥胖效果及安全性:系統性回顧與統合分析。
Cureus 2024-09-06